Anti-tumor CTL (Cytotoxic T Lymphocyte) epitope peptide from MTA1 (Tumor Metastasis Associated Antigen 1) and application thereof
An epitope peptide, anti-tumor technology, applied in anti-tumor drugs, medical preparations containing active ingredients, peptides, etc.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment Construction
[0015] The anti-tumor CTL epitope peptide derived from MTA1 of the present invention includes a nonapeptide, and the amino acid sequence of the nonapeptide is
[0016] P22: Tyr-Leu-Ile-Arg-Arg-Ile-Glu-Glu-Leu
[0017] or P57: Ala-Leu-Ala-Asp-Lys-His-Ala-Thr-Leu
[0018] or P109: Phe-Leu-Ser-Arg-Gln-Leu-Glu-Ser-Leu
[0019] or P129: Thr-Leu-Leu-Asn-Glu-Thr-Glu-Ser-Leu
[0020] or P173: Tyr-Gln-Ala-Asp-Ile-Thr-Asp-Leu-Leu.
[0021] The present invention mainly adopts the method of combining theory and practice, according to the primary structure of the antigen, adopts immunoinformatics means, and uses SYFPEITHI, BIMAS, NetCTL 1.2 and IEDB databases to analyze the HLA-A*0201 restricted CTL epitope of the MTA1 protein antigen Predictive analysis was performed.
[0022] The above-mentioned epitope peptides were screened and synthesized using the standard Fmoc protocol. After HPLC purification, the purity was greater than 90%. Mass spectrometry analysis confirmed that the molecu...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 